SSE: 688506
Announcement on Appointment of Securities Affairs RepresentativeThe abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
View Attachment
(688506)"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Appointment of Securities Affairs Representative
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
View Attachment
View original source (Shanghai Stock Exchange)
Earlier from Sichuan Biokin Pharmaceutical Co., Ltd. Class A
- (688506)"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Inclusion of T-Bren (HER2 ADC) in the List of Breakthrough Therapy Designations for Patients with HER2-Expressing Locally Advanced or Metastatic Biliary Tract Cancer Who Have Failed Platinum-based Chemotherapy
- (688506)"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Inclusion of iza-bren (izalontamab brengitecan, BL-B01D1) in the List of Breakthrough Therapy Designations for Patients with Recurrent or Metastatic Biliary Tract Cancer Who Have Failed Prior Platinum-based Chemotherapy
- (688506)"SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Receipt of the Clinical Trial Approval Notice for BL-M12D1 for Injection (ADC) for the Treatment of Hematological Malignancies
- "SICHUAN BIOKIN PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Inclusion of BL-M05D1 for Injection in the List of Breakthrough Therapy Designations for Patients with CLDN18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Who Have Previously Received First-line Standard Treatment